H.C. Wainwright analyst Andres Y. Maldonado has maintained their bullish stance on CGON stock, giving a Buy rating on September 10.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Andres Y. Maldonado has given his Buy rating due to a combination of factors that highlight the potential of CG Oncology, Inc.’s product, Creto. The recent pricing decision by J&J for Inlexzo at the high end of the oncology market validates the value of bladder preservation therapies, positioning Creto as a competitive player in a lucrative market. Maldonado’s analysis suggests that even with a conservative pricing model for Creto, the therapy can achieve significant market penetration and revenue, given its simpler administration and better tolerability compared to Inlexzo.
Moreover, the unmet medical need and the potential for Creto to be used sequentially with other therapies provide a strong foundation for its market success. The forecasted sales growth for Creto, from $76 million in 2026 to $2.6 billion by 2034, supports the Buy rating, as it underscores the long-term revenue potential despite the competitive landscape. Maldonado’s assessment also considers the strategic pricing flexibility that CG Oncology has, which could either match J&J’s premium pricing or adopt a more disruptive approach, both of which are expected to yield substantial financial returns.
Y. Maldonado covers the Healthcare sector, focusing on stocks such as I-MAB, ImmunityBio, and Merus. According to TipRanks, Y. Maldonado has an average return of 8.6% and a 49.64% success rate on recommended stocks.
In another report released on September 10, Piper Sandler also reiterated a Buy rating on the stock with a $55.00 price target.